Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era.
Fiche publication
Date publication
juillet 2013
Journal
BMC medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A
Lien Pubmed
Résumé
Lung cancer is the leading cause of cancer death worldwide in part due to our inability to identify which smokers are at highest risk and the lack of effective tools to detect the disease at its earliest and potentially curable stage. Recent results from the National Lung Screening Trial have shown that annual screening of high-risk smokers with low-dose helical computed tomography of the chest can reduce lung cancer mortality. However, molecular biomarkers are needed to identify which current and former smokers would benefit most from annual computed tomography scan screening in order to reduce the costs and morbidity associated with this procedure. Additionally, there is an urgent clinical need to develop biomarkers that can distinguish benign from malignant lesions found on computed tomography of the chest given its very high false positive rate. This review highlights recent genetic, transcriptomic and epigenomic biomarkers that are emerging as tools for the early detection of lung cancer both in the diagnostic and screening setting.
Mots clés
Early Diagnosis, Epigenesis, Genetic, genetics, Gene Expression Profiling, methods, Genetic Markers, genetics, Genome-Wide Association Study, methods, Humans, Lung Neoplasms, diagnosis, Mass Screening, methods, Risk Factors
Référence
BMC Med. 2013 Jul 19;11:168